MUMBAI, India, April 10 -- Intellectual Property India has published a patent application (202411072436 A) filed by Amity University, Noida, Uttar Pradesh, on Sept. 25, 2024, for 'a formulation for pimecrolimus-loaded nanolipid carriers in hydrogel for cle treatmentand method thereof.'
Inventor(s) include Shikha Baghel Chauhan; Indu Singh; and Kallepalli Surya Badarinadh.
The application for the patent was published on April 10, under issue no. 15/2026.
According to the abstract released by the Intellectual Property India: "The present invention relates to an optimized formulation of pimecrolimus-loaded nanolipid carriers (NLCs) incorporated into a hydrogel for the treatment of cutaneous lupus erythematosus (CLE). Lipids were selected based on Hansen solubility parameters to ensure compatibility and optimal 7 solubilization of pimecrolimus. NLCs were prepared using high shear homogenization with a focus on optimizing homogenization speed and the ratio of liquid lipid to solid lipid. These NLCs were then incorporated into a 2% hydrogel formulated with Carbopol 934. Optimization was guided by responses including particle size, polydispersity index (PDI), and entrapment efficiency, analyzed using a central composite design (CCD). The optimized formulation achieved a particle size of 31.3nm, a PDI of 14 0.173, and an entrapment efficiency of 97%. In vitro studies demonstrated 97.8% pimecrolimus release over 24 hours, while ex vivo studies confirmed a cumulative drug release of 9.8mg/mL with a biphasic release pattern. Histopathology and confocal analysis indicated good skin compatibility and effective penetration. This optimized NLC hydrogel formulation enhances the topical treatment of CLE, presenting a promising advance in dermatological therapies."
Disclaimer: Curated by HT Syndication.
